Aberrant Immune Features after Recovery from COVID-19 in Patients with Systemic Lupus Erythematosus and Other Autoimmune Diseases

被引:0
|
作者
Yu, Siyue [1 ]
Li, Hao [1 ]
Zhang, Kai [1 ]
Cheng, Gong [1 ]
Wang, Yifan [1 ]
Jia, Yuan [1 ]
Su, Linchong [2 ]
Jin, Yuebo [1 ]
Shao, Miao [1 ]
He, Jing [1 ]
机构
[1] Peking Univ Peoples Hosp, Dept Rheumatol & Immunol, Beijing 100044, Peoples R China
[2] Hubei Minzu Univ, Hubei Prov Key Lab Occurrence & Intervent Rheumat, Enshi 430074, Peoples R China
关键词
COVID-19; pandemic influenza; immunology mechanisms; broad immune response; regulatory T cell;
D O I
10.3390/biomedicines11102807
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Considering the large number of individuals who have already been infected and may have reinfection, the post-infection effects of COVID-19 are of great importance for clinical practice and predicting disease trends. However, our understanding of the potential long-term effects, particularly on immunity, after recovering from COVID-19 remains limited. The aim of this study was to investigate the abnormal immunological factors that contribute to the prolonged immunological effects of COVID-19. Two groups of patients were enrolled in the study, including 11 individuals with various autoimmune diseases (AIDs) and 16 patients diagnosed with systemic lupus erythematosus (SLE). Detailed clinical symptoms were closely monitored, and peripheral mononuclear cells were analyzed using flow cytometry. The clinical status was evaluated using the SLE Disease Activity Index (SLEDAI) and the Clinical Global Impressions (CGI) index. The proportions of follicular T helper cells (Tfh) exhibited significant increases in both cohorts (AID: p = 0.03; SLE: p = 0.0008). Conversely, the percentages of Foxp3(+) and CD4(+) regulatory T cells (Treg) were reduced in patients following COVID-19 infection (AID: p = 0.009, 0.05, resp.; SLE: p = 0.02, 0.0009, resp.). The percentages of Th2 and Th17 cells were significantly increased in SLE patients (p < 0.05). Exacerbated conditions were observed in SLE patients two months after infection (SLEDAI, p < 0.05). Our findings show that COVID-19 infection increases Tfh cells and decreases Treg cells in patients of AIDs, worsening pathogenetic immune status in post-recovery populations.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus
    Bruera, Sebastian
    Lei, Xiudong
    Zhao, Hui
    Yazdany, Jinoos
    Chavez-MacGregor, Mariana
    Giordano, Sharon H.
    Suarez-Almazor, Maria E.
    LUPUS SCIENCE & MEDICINE, 2023, 10 (01):
  • [42] Hydroxychloroquine and COVID-19: can we learn from the use of rituximab in systemic lupus erythematosus?
    Lekpa, Fernando Kemta
    Ngahane, Bertrand Hugo Mbatchou
    Njonnou, Sylvain Raoul Simeni
    Fouda, Hermine
    Halle, Marie Patrice
    Njankouo, Yacouba Mapoure
    Dzudie, Anastase
    Choukem, Simeon Pierre
    Luma, Henry Namme
    PAN AFRICAN MEDICAL JOURNAL, 2021, 38
  • [43] NET Formation in Systemic Lupus Erythematosus: Changes during the COVID-19 Pandemic
    Knopf, Jasmin
    Sjowall, Johanna
    Frodlund, Martina
    Hinkula, Jorma
    Herrmann, Martin
    Sjowall, Christopher
    CELLS, 2022, 11 (17)
  • [44] NETosis promotes chronic inflammation and fibrosis in systemic lupus erythematosus and COVID-19
    Lin, Huiqing
    Liu, Jiejie
    Li, Ning
    Zhang, Birong
    Nguyen, Van Dien
    Yao, Peipei
    Feng, Jiangpeng
    Liu, Qianyun
    Chen, Yu
    Li, Guang
    Zhou, You
    Zhou, Li
    CLINICAL IMMUNOLOGY, 2023, 254
  • [45] Acute respiratory distress syndrome and COVID-19 in a child with systemic lupus erythematosus
    Sukhdeo, Simone
    Negroponte, Emily
    Rajasekhar, Hariprem
    Gaur, Sunanda
    Horton, Daniel B.
    Malhotra, Amisha
    Moorthy, L. Nandini
    LUPUS, 2021, 30 (05) : 836 - 839
  • [46] The first case of systemic lupus erythematosus (SLE) triggered by COVID-19 infection
    Bonometti, R.
    Sacchi, M. C.
    Stobbione, P.
    Lauritano, E. C.
    Tamiazzo, S.
    Marchegiani, A.
    Novara, E.
    Molinaro, E.
    Benedetti, I
    Massone, L.
    Bellora, A.
    Boverio, R.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (18) : 9695 - 9697
  • [47] Systemic lupus erythematosus and COVID-19: what we know so far
    Ramirez, Giuseppe. A. A.
    Moroni, Luca
    Della-Torre, Emanuel
    Gerosa, Maria
    Beretta, Lorenzo
    Bozzolo, Enrica. P. P.
    Dagna, Lorenzo
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (03)
  • [48] COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus
    Giannopoulou, Nefeli
    Gupta, Latika
    Andreoli, Laura
    Lini, Daniele
    Nikiphorou, Elena
    Aggarwal, Rohit
    Agarwal, Vikas
    Parodis, Ioannis
    AUTOIMMUNITY REVIEWS, 2023, 22 (04)
  • [49] Outcome of COVID-19 in patients with autoimmune bullous diseases
    De, Dipankar
    Ashraf, Raihan
    Mehta, Hitaishi
    Handa, Sanjeev
    Mahajan, Rahul
    INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2023, 89 (06) : 862 - 866
  • [50] Medication adherence in systemic lupus erythematosus during Brazilian COVID-19 pandemic
    Albuquerque, Emmanuele S.
    Pinto, Larissa D. S.
    Neto, Valfrido LdM
    Fragoso, Thiago S.
    LUPUS, 2022, 31 (02) : 221 - 227